S A Waldman

Summary

Affiliation: Thomas Jefferson University
Country: USA

Publications

  1. ncbi request reprint Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro
    S A Waldman
    Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Epidemiol Biomarkers Prev 7:505-14. 1998
  2. pmc Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells
    G M Pitari
    Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 98:7846-51. 2001
  3. pmc Can colorectal cancer be prevented or treated by oral hormone replacement therapy?
    P Li
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Curr Mol Pharmacol 2:285-92. 2009
  4. pmc Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy
    P Li
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA
    Clin Transl Sci 1:163-7. 2008
  5. ncbi request reprint Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen
    A E Snook
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 82:734-9. 2007
  6. ncbi request reprint Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood
    T A Fava
    Division of Clinical Pharmacology, and Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 19:3951-9. 2001
  7. ncbi request reprint The paracrine hormone hypothesis of colorectal cancer
    G M Pitari
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 82:441-7. 2007
  8. ncbi request reprint Colorectal cancer staging and adjuvant chemotherapy
    A Gelmann
    Division of Clinical Pharmacology, Departments of Medicine and Biochemistry and Molecular Pharmacology, Jefferson Medical College, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA
    Expert Opin Pharmacother 1:737-55. 2000
  9. pmc Guanylyl cyclase is an ATP sensor coupling nitric oxide signaling to cell metabolism
    I Ruiz-Stewart
    Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 101:37-42. 2004
  10. pmc Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues
    S L Carrithers
    Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 93:14827-32. 1996

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Heterogeneity of guanylyl cyclase C expressed by human colorectal cancer cell lines in vitro
    S A Waldman
    Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Epidemiol Biomarkers Prev 7:505-14. 1998
    ....
  2. pmc Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells
    G M Pitari
    Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 98:7846-51. 2001
    ..Therefore, GC-C ligands may be novel therapeutic agents for the treatment of patients with colorectal cancer...
  3. pmc Can colorectal cancer be prevented or treated by oral hormone replacement therapy?
    P Li
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Curr Mol Pharmacol 2:285-92. 2009
    ..The correlative therapeutic hypothesis suggests that colorectal cancer is a disease of hormone insufficiency that can be prevented or treated by oral supplementation with GCC ligands...
  4. pmc Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy
    P Li
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA
    Clin Transl Sci 1:163-7. 2008
    ..Together with the uniform over-expression of GCC in human tumors, these novel roles for GCC underscore the potential of oral replacement with GCC ligands for targeted prevention and therapy of colorectal cancer...
  5. ncbi request reprint Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen
    A E Snook
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 82:734-9. 2007
    ..Guanylyl cyclase C (GCC) is an intestine/colorectal cancer-restricted protein ideally suited as the first CMA for clinical evaluation...
  6. ncbi request reprint Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood
    T A Fava
    Division of Clinical Pharmacology, and Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 19:3951-9. 2001
    ....
  7. ncbi request reprint The paracrine hormone hypothesis of colorectal cancer
    G M Pitari
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 82:441-7. 2007
    ....
  8. ncbi request reprint Colorectal cancer staging and adjuvant chemotherapy
    A Gelmann
    Division of Clinical Pharmacology, Departments of Medicine and Biochemistry and Molecular Pharmacology, Jefferson Medical College, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA
    Expert Opin Pharmacother 1:737-55. 2000
    ....
  9. pmc Guanylyl cyclase is an ATP sensor coupling nitric oxide signaling to cell metabolism
    I Ruiz-Stewart
    Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 101:37-42. 2004
    ..Hence, sGC forms a key synapse integrating metabolic, energetic, and cell signaling, wherein ATP is the transmitter, allosteric inhibition the coupling mechanism, and regulated accumulation of cGMP the response...
  10. pmc Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues
    S L Carrithers
    Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 93:14827-32. 1996
    ....
  11. pmc Bacterial enterotoxins are associated with resistance to colon cancer
    G M Pitari
    Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 100:2695-9. 2003
    ....
  12. ncbi request reprint Nucleotide requirements for CDX2 binding to the cis promoter element mediating intestine-specific expression of guanylyl cyclase C
    M D Di Guglielmo
    Division of Clinical Pharmacology, Departments of Medicine, Biochemistry and Molecular Pharmacology, Thomas Jefferson University, 812 Medical Office Building, 1100 Walnut Street, Philadelphia, PA 19107, USA
    FEBS Lett 507:128-32. 2001
    ..These studies describe the precise nucleotide sequence within the GC-C promoter that comprises the CDX2 binding site required for intestine-specific expression...
  13. pmc Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma
    D S Weinberg
    Division of Gastroenterology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    J Clin Invest 100:597-603. 1997
    ..Because of its selective expression, the CCK-A receptor may serve as selective biomarker for pancreatic adenocarcinoma...
  14. ncbi request reprint Tumor-targeting peptide-PNA-peptide chimeras for imaging overexpressed oncogene mRNAs
    X Tian
    Biochemistry and Molecular Pharmacology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Nucleosides Nucleotides Nucleic Acids 24:1085-91. 2005
    ..In vivo scintigraphic imaging of MCF7 xenografts in immunocompromised mice indicated that CCND1 and MYC [99sTc] chelator-PNA-D (CSKC) probes concentrated in MCF7 cells up to 7 times more than the corresponding mismatch controls...
  15. ncbi request reprint Guanylyl cyclases and signaling by cyclic GMP
    K A Lucas
    Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Pharmacol Rev 52:375-414. 2000
    ..A brief overview is presented of the downstream events controlled by guanylyl cyclases, including the effectors that are regulated by cGMP and the role that guanylyl cyclases play in cell physiology and pathophysiology...
  16. doi request reprint Molecular insights provide the critical path to disease mitigation
    S A Waldman
    1 Department of Pharmacology and Experimental Therapeutics, Delaware Valley Institute for Clinical and Translational Science 2 Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 95:3-7. 2013
    ....
  17. doi request reprint Antiobesity pharmacotherapy: new drugs and emerging targets
    G W Kim
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 95:53-66. 2013
    ..Clinical Pharmacology & Therapeutics (2013); 95 1, 53-66 advance online publication 13 November 2013. doi:10.1038/clpt.2013.204. ..
  18. doi request reprint Managing the innovation supply chain to maximize personalized medicine
    S A Waldman
    1 Department of Pharmacology and Experimental Therapeutics, Delaware Valley Institute for Clinical and Translational Science 2 Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 95:113-8. 2014
    ....
  19. doi request reprint Systems-based discovery advances drug development
    S A Waldman
    1 Department of Pharmacology and Experimental Therapeutics, Delaware Valley Institute for Clinical and Translational Science 2 Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 93:285-7. 2013
    ..Driven by advances in biology, engineering, and informatics, new paradigms integrate phenotypic with target-based algorithms into comprehensive, systems-level approaches offering value-added strategies for optimized drug discovery...
  20. doi request reprint Information hierarchies optimize patient-centered solutions
    S A Waldman
    Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 93:3-7. 2013
    ..This annual issue on therapeutics innovations highlights emerging considerations for the generation and hierarchical organization of scientific and clinical information and its translation to advancing next-generation disease management...
  21. doi request reprint Advancing pharmacometrics and systems pharmacology
    S A Waldman
    Department of Pharmacology and Experimental Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 92:535-7. 2012
    ....
  22. pmc Central and peripheral molecular targets for antiobesity pharmacotherapy
    M A Valentino
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
    Clin Pharmacol Ther 87:652-62. 2010
    ..These studies have revealed previously unrecognized molecular targets for controlling appetite and managing weight from which has emerged a new wave of targeted pharmacotherapies to prevent and control obesity...